Individual cells are the foundation of the human body. How cells work together defines who we are, how we function and the diseases we have. Now, for the first time, we are able to see how individual cells interact at a level of resolution that was not previously possible.
We are on a quest to leverage the power of single-cell RNA sequencing to discover precision therapeutics for complex diseases such as autoimmunity and cancer. These diseases are comprised of many different cells, making them difficult to understand and to treat effectively. Combining massive datasets of unprecedented complexity and sophisticated machine learning algorithms allows us to understand the specific cells, among many others, that are causing the disease, and to identify the genes that are triggering their malfunction. With this new level of clarity, this approach has the unique potential to deliver a powerful new class of medicines and make a meaningful difference for patients.
Product engineFiercely committed to responsibly executing with speed and excellence to bring transformative therapies to patients in need
Bringing our community together to create strong, collaborative relationships in an ecosystem that inspires us to work tirelessly to make a difference
Constantly exploring new ideas and perspectives that motivate us to never stop innovating and making meaningful discoveries
July 9
Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study CAMBRIDGE, Mass., July 9, 2019 – Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, today announced a collaboration with Janssen Biotech, Inc. Under the terms […]
June 11
Experienced biopharma leader brings business development, strategy and company-building expertise to accelerate Celsius’ growth
You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.
